Aflibercept is a recombinant fusion protein belonging to the VEGF Trap class, engineered to bind vascular endothelial growth factor to effectively inhibit angiogenesis. This therapeutic agent is clinically… Read more
Aflibercept is a recombinant fusion protein belonging to the VEGF Trap class, engineered to bind vascular endothelial growth factor to effectively inhibit angiogenesis. This therapeutic agent is clinically indicated for the management of conditions such as wet age-related macular degeneration and metastatic colorectal cancer. To support rigorous analytical testing, this category provides a comprehensive selection of Aflibercept reference standards, including pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. Pharmaceutical laboratories utilize these high-quality materials for critical tasks such as impurity profiling, the validation of analytical methods, and routine quality control of final drug formulations. By incorporating these specific compounds into testing protocols, researchers ensure the consistency, safety, and regulatory compliance of Aflibercept-based medicinal products throughout the drug development and manufacturing lifecycle.